{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006349","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.102992+00:00","generated_at":"2026-06-18T09:49:56.312475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEAYA reports cash $373.1M, net loss $58.7M; darovasertib data mid-2023","bullets":["Cash, cash equivalents and marketable securities $373.1M as of Dec 31, 2022; sufficient to fund operations into 2026.","Net loss $58.7M for FY2022 vs $49.8M in FY2021; Q4 collaboration revenue $4.0M vs $3.0M.","Targeting mid-2023 clinical efficacy update for darovasertib/crizotinib in ~20 first-line MUM patients; goals: >20% ORR, >5 months mPFS.","First-patient dosing of IDE161 (PARG) in Q1 2023; IND submission for Pol Theta Helicase in Q2 2023 with GSK.","Discontinuing IDE397+chemo cohorts; prioritizing IDE397/AMG193 combination with Amgen."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006349","json":"https://secwatch.observer/filing/0000950170-23-006349.json","markdown":"https://secwatch.observer/filing/0000950170-23-006349.md","text":"https://secwatch.observer/filing/0000950170-23-006349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/0000950170-23-006349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/idya-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:49:56.312475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b447b6f73871506f859a552543b19cc25a7870ae","claim":"IDEAYA Biosciences, Inc. reported financial results for year ended December 31, 2022.","evidence_excerpt":"On March 7, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/0000950170-23-006349-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}